Concern over COVID-19 stems not only from its high degree of virulence, but from its ability to continuously mutate and produce new variants. An effective vaccine can help slow the virus’ spread, but the question of how to deal with its continuous mutations is key.
Mass production of the most well-known novel coronavirus vaccines in production, including by AstraZeneca PLC, Moderna Inc and Pfizer Inc, has a high technological threshold, especially for those using messenger RNA (mRNA) technology, since manufacturers need to overcome the challenges of storage and transportation at ultra-low temperatures.
Founded in 2018, Ascendo Biotechnology Inc (先知生技) has a research and development team with 30 years of clinical drug research experience, focused on immune-related drug research.
Photo courtesy of Ascendo Biotechnology Inc
Using quantum mechanics technologies, Ascendo has developed a proprietary NanoCherubTM electric-kinetic nanocomplex antigen adjuvant and delivery platform, designed to rapidly respond to mutations without the challenges of ultra-low temperature storage and transportation, and to produce large quantities of vaccines quickly
‧ NanoCherubTM in the fight against COVID-19
Doctors and scientists have been racking their brains for a solution to the constantly mutating virus. Using quantum mechanics calculations, Ascendo can produce effective vaccines quickly, with a precise and flexible technology circumventing the need for the constant testing of more traditional approaches.
Last year, Ascendo started working with academic research institutions in Taiwan on developing a COVID-19 vaccine, for the first time using quantum mechanics technology to design a drug delivery system encapsulating antigens to form a positively charged nanocomplex, enabling immune cells to generate a strong and effective response to the NanoCherubTM Electric-Kinetic nanocomplex and achieving a balanced and robust Th1/Th2 immunity.
The ASD254 vaccine developed by Ascendo last year showed excellent results in animal studies using mice, which most closely replicate the symptoms of the novel coronavirus in humans.
All vaccinated animals received 100 percent immune protection when tested with the live virus. Ascendo soon plans to apply to the Food and Drug Administration for phase 1 human trials, hoping to enter mass production next year.
The drug delivery platform can significantly shorten development times and respond to virus mutations, and the NanoCherubTM Electric-Kinetic nanocomplex can consistently induce balanced and strong Th1/Th2 immunity against encapsulated antigens, including full pathogens, subunit proteins, peptides and messenger ribonucleic acid, with the added advantage of the vaccines only needing to be stored at 2°C to 8°C.
‧ Hepatitis B therapeutic vaccine completed in animal efficacy trials
Ascendo has also completed animal efficacy trials for its ASD253 vaccine for chronic hepatitis B. Following preclinical trials, Phase 1 human trials are to begin next year, when ASD253 is expected to become the world’s first vaccine for chronic hepatitis B.
The company also hopes to develop vaccines for HIV (AIDS), dengue fever, Zika and pan-influenza viruses.
Taiwan’s foreign exchange reserves fell below the US$600 billion mark at the end of last month, with the central bank reporting a total of US$596.89 billion — a decline of US$8.6 billion from February — ending a three-month streak of increases. The central bank attributed the drop to a combination of factors such as outflows by foreign institutional investors, currency fluctuations and its own market interventions. “The large-scale outflows disrupted the balance of supply and demand in the foreign exchange market, prompting the central bank to intervene repeatedly by selling US dollars to stabilize the local currency,” Department of Foreign
Intel Corp is joining Elon Musk’s long-shot effort to develop semiconductors for Tesla Inc, Space Exploration Technologies Corp and xAI, marking a surprising twist in the chipmaker’s comeback bid. Intel would help the Terafab project “refactor” the technology in a chip factory, the company said on Tuesday in a post on X, Musk’s social media platform. That is a stage in the development process that typically helps make chips more powerful or reliable. The chipmaker’s shares jumped 4.2 percent to US$52.91 in New York trading on Tuesday. The Terafab project is a grand plan by Musk to eventually manufacture his own chips for
Taiwan Power Co (Taipower, 台電) yesterday said it plans to resume operations at two coal-fired power generators for three months to boost security of electricity supply as liquefied natural gas (LNG) supply risks are running high due to the Middle East conflict. The two coal-fired power generators are at Mailiao Power Plant in Yunlin County’s Mailiao Township (麥寮). The plant, operated by Formosa Plastics Group (台塑集團), supplied electricity to Taipower’s power grid until the end of last year. Taipower’s decision came about one month after Minister of Economic Affairs Kung Ming-hsin (龔明鑫) on March 10 said that the nation had no imminent
Some robotaxi passengers were left stranded in the middle of fast-moving traffic in a major Chinese city after their driverless vehicles stopped running, according to police and media reports on Wednesday. A preliminary investigation indicates more than 100 robotaxis came to a halt because of a “system malfunction,” police in the city of Wuhan said in a statement, without elaborating. No injuries were reported. One passenger told Chinese media that their robotaxi stopped after turning a corner. An instruction on a screen read: “Driving system malfunction. Staff are expected to arrive in 5 minutes.” After no one showed up, the passenger pushed
RSS